Sofinnova leads €12.3m round for Highlife

Following the deal, Sofinnova will become the largest shareholder in the business, according to a statement. Other shareholders include corporate investor LivaNova and the company's CEO and founder Georg Börtlein.

The deal marks the second time that Sofinnova has invested in a company led by Börtlein: in 2004, the VC injected $6m in growth capital into CoreValve, a trans-catheter aortic valve implantation developer, subsequently sold to Medtronic for $700m in 2009. The CoreValve deal returned more than 10x the VC's original investment.

Company
Highlife was founded in 2010 and is based in Paris, with an additional presence in California. It develops medical device focusing on the replacement of the trans-catheter mitral valve for patients suffering from mitral regurgitation.

People
Sofinnova Partners – Antonie Papiernik (managing partner).
Highlife – Georg Börtlein (founder, CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• France
• Venture
• France
• Sofinnova Partners